Employees: 196
Size Jacobio Pharmaceuticals (1167.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $404M, the 805th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$4.10 on 18 Nov 2026.
Performance Over six months the shares fell 23.6%, against -22.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 286.2% over the last twelve months (peer median +9.6%); the operating margin is 68.0% (peer median -7.2%).
Valuation It trades at 5.7× forward earnings against a peer median of 26.2× (cheapest of 7).
Price implies For today's price to make sense, revenue must grow about -19% a year for seven years (Req g). Recent delivered growth is -36%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$842M | HK$58.0M | HK$169M | HK$70.2M | HK$111M |
| Revenue growth | — | -66% | +141% | -37% | — |
| Gross profit | HK$795M | HK$32.7M | HK$140M | -HK$23.4M | HK$62,795 |
| EBITDA | HK$598M | -HK$160M | -HK$207M | -HK$432M | -HK$537M |
| Net income | HK$589M | -HK$158M | -HK$169M | -HK$397M | -HK$432M |
| Free cash flow | HK$622M | -HK$208M | -HK$55.3M | -HK$423M | -HK$362M |
| Capital expenditure | HK$1.76M | HK$1.81M | HK$13.1M | HK$42.7M | HK$19.2M |
| Total debt | n/a | HK$359M | HK$275M | HK$296M | HK$166M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1167.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.4% | -11.3% | 2nd lowest of 21 |
| 6-month return | -23.6% | -22.0% | 9th lowest of 21 |
| Distance from 52-week high | -55.9% | -40.6% | 6th lowest of 21 |
| Revenue growth (TTM) | +286.2% | +9.6% | 3rd highest of 17 |
| Operating margin | 68.0% | -7.2% | highest of 17 |
| Forward P/E | 5.7× | 26.2× | cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | -18.8% | 4.6% | 2nd least demanding of 7 |
| Growth delivered (Del g) | -36.1% | +37.6% | 2nd lowest of 6 |
| Hurdle (Req g minus delivered) | +17.4 pp | +14.3 pp | 3rd most demanding of 6 |
| EV / EBITDA | 2.7× | 5.2× | cheapest of 4 |
| Net debt / EBITDA | -2.6× | -2.1× | 2nd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 5.7× | -18.8% | -36.1% |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | n/a | n/a | n/a |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | n/a | -15.3% | +197.3% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | 26.2× | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | n/a | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | n/a | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | n/a | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | n/a | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | n/a | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 16.2× | 36.6% | +8.9% |
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 84.0× | 51.9% | +37.6% |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | n/a | 4.0% | -62.3% |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 170.0× | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 26.2× | 5.3% | +70.5% |
| Alector ALEC | United States | $383M | +21% | +151% | 25% | n/a | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 10.2× | -19.5% | n/a |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | n/a | n/a | n/a |